SavedAdd your journal

Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 4

The predictive value of maternal serum screening tests for adverse pregnancy outcomes

Gultekin ADANAS AYDİN
Gulten OZGEN
Pages
1268–1274
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No significant correlation was found between preeclampsia and the serum markers.Conclusion: Our results show that elevated maternal serum AFP levels might be associated with various APOs,requiring closerpatient follow-up for early diagnosis and treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractAim: Free beta-human chorionic gonadotropin (Fβ-hCG), pregnancy-associated plasma protein-A (PAPP-A), alpha-fetoprotein (AFP), unconjugated estriol (uE3), and inhibin-A have been shown to be useful not only in identifying chromosomal abnormalities in the first and second trimesters, but also in predicting adverse pregnancy outcomes (APOs).
📊
Key Findings & Data:In this study, we aimed to investigate the predictive value of maternal serum screening tests for various APOs including preeclampsia, intrauterine growth retardation (IUGR), preterm labor, and gestational diabetes mellitus (GDM).Material and Methods: The study was carried out at our clinics and included a total of 220 pregnant women who respectively underwent the double and quadruple marker testsduring the 11th to 14th and 15th to 22nd gestational weeksbetween January 2017 and December 2018.
💡
Conclusion & Impact:No significant correlation was found between preeclampsia and the serum markers.Conclusion: Our results show that elevated maternal serum AFP levels might be associated with various APOs,requiring closerpatient follow-up for early diagnosis and treatment.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

AbstractAim: Free beta-human chorionic gonadotropin (Fβ-hCG), pregnancy-associated plasma protein-A (PAPP-A), alpha-fetoprotein (AFP), unconjugated estriol (uE3), and inhibin-A have been shown to be useful not only in identifying chromosomal abnormalities in the first and second trimesters, but also in predicting adverse pregnancy outcomes (APOs). In this study, we aimed to investigate the predictive value of maternal serum screening tests for various APOs including preeclampsia, intrauterine growth retardation (IUGR), preterm labor, and gestational diabetes mellitus (GDM).Material and Methods: The study was carried out at our clinics and included a total of 220 pregnant women who respectively underwent the double and quadruple marker testsduring the 11th to 14th and 15th to 22nd gestational weeksbetween January 2017 and December 2018. Patient data (maternal age, parity/gravidity, gestational age, history of infertility, use of in vitro fertilization, maternal/ fetal complications, preterm labor, mode of delivery, birth weight, and length of stay in the neonatal intensive care unit) were reviewed retrospectively.Results: The AFP levels were statistically significantly higher in patients with IUGR (p=0.022),GDM (p=0.036), and preterm labor (p=0.021), compared to the control group with no APO. No significant correlation was found between preeclampsia and the serum markers.Conclusion: Our results show that elevated maternal serum AFP levels might be associated with various APOs,requiring closerpatient follow-up for early diagnosis and treatment.

🔖

Cite This Article

AYDİN, G. A., OZGEN, G. (2022). The predictive value of maternal serum screening tests for adverse pregnancy outcomes. Annals of Medical Research, Cilt: 27 - Sayı: 4, 1268–1274. https://ajindex.com/articles/446243

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Pergament E, Stein AK, Fiddler M, et al. Adverse pregnancy outcome after a false-positive screen for Down syndrome using multiple markers.Obstet Gynecol 1995;86:255-8
  2. Alldred SK, Deeks JJ, Guo B, et al. Second trimester serum tests for Down’s syndrome screening. Cochrane Database Syst Rev 2012;6:CD009925
  3. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77
  4. Palomaki GE, Steinort K, Knight GJ, et al. Comparing three screening strategies for combining first-and second-trimester Down syndrome markers. Obstet Gynecol 2006;107:367-75
  5. Loucky J, Belaskova S, Prusa R, et al. The effect of inhibinA on prenatal screening results for Down syndrome in the high risk Czech pregnant women. Clin Lab 2019;65
  6. Kaewsuksai P, Jitsurong S. Prospective study of the feasibility and effectiveness of a second-trimester quadruple test for Down syndrome in Thailand.Int J Gynaecol Obstet 2017;139:217-21
  7. Alldred SK, Takwoingi Y, Guo B, et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening. Cochrane Database Syst Rev 2017;3:CD012599
  8. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome.Obstet Gynecol 2005;106:260-7
  9. Lao MR, Calhoun BC, Bracero LA, et al. The ability of the quadruple test to predict adverse perinatal outcomes in a high-risk obstetric population. J Med Screen 2009;16:55-9
  10. Baer RJ, Currier RJ, Norton ME, et al. Obstetric, perinatal, and fetal outcomes in pregnancies with false-positive integrated screening results. Obstet Gynecol 2014;123:603-9
  11. Cuckle HS. Screening for pre-eclampsia-lessons from aneuploidy screening. Placenta 2011;32:42-8
  12. Balci S. Prediction of poor pregnancy and poor neonatal outcomes. J Turk Ger Gynecol Assoc 2016;17:143-9
  13. Hughes AE, Sovio U, Gaccioli F, et al. The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome. Placenta 2019;81:25-31
  14. Gagnon A, Wilson RD. Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes.J Obstet Gynaecol Can 2008;30:918-32
  15. Singnoi W, Wanapirak C, Sekararithi R,et al. A cohort study of the association between maternal serum inhibin-A and adv